Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DWTX Dogwood Therapeutics	$4.71 -1.3%	$5.11	$1.62 ▼ $29.28	$9M	1.88	1.55 million shs	14,919 shs
MRSN Mersana Therapeutics	$0.29 -10.5%	$0.36	$0.26 ▼ $2.83	$36.27M	0.83	2.69 million shs	15.79 million shs
SKYE Skye Bioscience	$4.11 -3.3%	$2.38	$1.14 ▼ $8.26	$127.31M	1.69	479,709 shs	7.48 million shs
SPRO Spero Therapeutics	$2.94 +1.4%	$1.63	$0.51 ▼ $3.09	$164.38M	1.31	1.20 million shs	1.69 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DWTX Dogwood Therapeutics	0.00%	-3.88%	-10.96%	-16.49%	+470,999,900.00%
MRSN Mersana Therapeutics	0.00%	-20.47%	-16.62%	-23.32%	-85.59%
SKYE Skye Bioscience	0.00%	+90.28%	+91.61%	+119.08%	-46.41%
SPRO Spero Therapeutics	0.00%	-2.65%	+38.03%	+281.82%	+121.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DWTX Dogwood Therapeutics	2.1579 of 5 stars	3.5	0.0	0.0	3.5	0.0	0.6
MRSN Mersana Therapeutics	3.9721 of 5 stars	3.5	1.0	4.1	3.3	2.5	0.0
SKYE Skye Bioscience	2.3786 of 5 stars	3.5	4.0	0.0	3.2	0.0	0.0
SPRO Spero Therapeutics	4.2895 of 5 stars	3.3	5.0	4.7	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DWTX Dogwood Therapeutics	3.00	Buy	$10.00	112.31% Upside
MRSN Mersana Therapeutics	3.00	Buy	$5.20	1,686.94% Upside
SKYE Skye Bioscience	3.00	Buy	$16.60	303.89% Upside
SPRO Spero Therapeutics	2.50	Moderate Buy	$5.00	70.07% Upside

Current Analyst Ratings Breakdown

Latest DWTX, MRSN, SKYE, and SPRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	SKYE Skye Bioscience	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/20/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/16/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
5/16/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/15/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$3.00
5/6/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$4.00 ➝ $3.00
4/23/2025	DWTX Dogwood Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$10.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	($7.56) per share	N/A
MRSN Mersana Therapeutics	$40.50M	0.90	N/A	N/A	($0.08) per share	-3.64
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$2.25 per share	N/A
SPRO Spero Therapeutics	$47.98M	3.43	N/A	N/A	$0.85 per share	3.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DWTX Dogwood Therapeutics	-$12.35M	-$18.04	N/A	N/A	N/A	N/A	-217.12%	-34.74%	8/6/2025 (Estimated)
MRSN Mersana Therapeutics	-$69.19M	-$0.59	N/A	N/A	N/A	-217.63%	-990.16%	-48.87%	8/12/2025 (Estimated)
SKYE Skye Bioscience	-$26.57M	-$0.82	N/A	N/A	N/A	N/A	-53.92%	-48.58%	N/A
SPRO Spero Therapeutics	-$68.57M	-$1.28	N/A	N/A	N/A	-156.48%	-123.50%	-58.96%	8/4/2025 (Estimated)

Latest DWTX, MRSN, SKYE, and SPRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	MRSN Mersana Therapeutics	-$0.21	-$0.19	+$0.02	-$0.19	$6.05 million	$2.75 million
5/13/2025	Q1 2025	SPRO Spero Therapeutics	-$0.55	-$0.25	+$0.30	-$0.25	$11.00 million	$5.87 million
5/8/2025	Q1 2025	DWTX Dogwood Therapeutics	-$0.77	-$4.21	-$3.44	-$8.45	N/A	N/A
5/8/2025	Q1 2025	SKYE Skye Bioscience	-$0.31	-$0.28	+$0.03	-$0.28	N/A	N/A
3/31/2025	Q4 2024	DWTX Dogwood Therapeutics	-$1.49	-$6.29	-$4.80	-$6.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DWTX Dogwood Therapeutics	N/A	7.43	7.43
MRSN Mersana Therapeutics	13.35	1.83	1.83
SKYE Skye Bioscience	N/A	11.85	11.85
SPRO Spero Therapeutics	N/A	2.56	2.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DWTX Dogwood Therapeutics	9.05%
MRSN Mersana Therapeutics	93.92%
SKYE Skye Bioscience	21.09%
SPRO Spero Therapeutics	25.60%

Insider Ownership

Company	Insider Ownership
DWTX Dogwood Therapeutics	3.90%
MRSN Mersana Therapeutics	13.00%
SKYE Skye Bioscience	4.50%
SPRO Spero Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DWTX Dogwood Therapeutics	5	1.91 million	1.84 million	N/A
MRSN Mersana Therapeutics	150	124.63 million	108.43 million	Optionable
SKYE Skye Bioscience	11	30.98 million	29.58 million	Optionable
SPRO Spero Therapeutics	150	55.91 million	52.84 million	Optionable

DWTX, MRSN, SKYE, and SPRO Headlines

Recent News About These Companies

While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership

June 28 at 10:04 AM | finance.yahoo.com

Spero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo Finance

June 26 at 6:35 PM | finance.yahoo.com

Spero Therapeutics (NASDAQ:SPRO) Upgraded to "Hold" at Wall Street Zen

June 21, 2025 | marketbeat.com

Spero Therapeutics (NASDAQ:SPRO) Shares Pass Above 200 Day Moving Average - What's Next?

June 19, 2025 | marketbeat.com

Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Up 446.6% in May

June 11, 2025 | marketbeat.com

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

June 11, 2025 | seekingalpha.com

Spero Therapeutics, Inc. (NASDAQ:SPRO) Stake Boosted by Mackenzie Financial Corp

June 6, 2025 | marketbeat.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | msn.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | insidermonkey.com

Best Penny Stocks To Watch Today - May 28th

May 30, 2025 | marketbeat.com

GSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMC

May 30, 2025 | pharmabiz.comP

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr

May 29, 2025 | thepharmaletter.comT

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone

May 29, 2025 | msn.com

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

May 29, 2025 | zacks.com

Spero Therapeutics Sees Unusually Large Options Volume (NASDAQ:SPRO)

May 29, 2025 | marketbeat.com

GSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soars

May 28, 2025 | endpts.comE

GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win

May 28, 2025 | fiercebiotech.comF

Spero Therapeutics Shares Soar as Trial with GSK Ends Early on Efficacy

May 28, 2025 | marketwatch.com

Spero Therapeutics Stock Skyrockets on Strong Phase 3 Trial Results

May 28, 2025 | msn.com

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

May 28, 2025 | globenewswire.com

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX, MRSN, SKYE, and SPRO Company Descriptions

Dogwood Therapeutics NASDAQ:DWTX

$4.71 -0.06 (-1.26%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.74 +0.03 (+0.53%)

As of 06/27/2025 06:33 PM Eastern

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Mersana Therapeutics NASDAQ:MRSN

$0.29 -0.03 (-10.46%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.32 +0.03 (+11.00%)

As of 06/27/2025 07:50 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Skye Bioscience NASDAQ:SKYE

$4.11 -0.14 (-3.29%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.15 +0.04 (+0.97%)

As of 06/27/2025 07:58 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Spero Therapeutics NASDAQ:SPRO

$2.94 +0.04 (+1.38%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.96 +0.02 (+0.85%)

As of 06/27/2025 07:42 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time